Michael L. Wang, MD, MD Anderson Cancer Center, Houston, TX, discusses the use of chimeric antigen receptor T-cell (CAR-T) therapy for patients with high-risk mantle cell lymphoma (MCL) in the frontline setting. High-risk factors include blastoid or pleomorphic MCL, complex karyotype, TP53 mutations and high KI-67 proliferation indices. Clinical trials investigating CAR-T therapy for patients with high-risk MCL are currently underway. CAR-T therapy is already being utilized in clinical practice as a second-line treatment for high-risk MCL. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.